Latigo Biotherapeutics Inc.
NASDAQ:LTGOMedical - Pharmaceuticals
+$0.76 today
- Market cap
- $800.64M
- Beta
- 0.00
Volume 0.21M
Average 0.38M
LTGO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Research & Development history
Currency unavailable · from the income statement
No Research & Development data reported for this period type.
Research & Development vs competitors
How LTGO compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $119.69M USD | +35.0% | +11.4% | 16.3% | |
| LTM Mar 2026 | $21.46M USD | +138.8% | +31.8% | 63.4% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — | — |
| Peer median (excluding LTGO) | — | +86.9% | +21.6% | 16.3% | |
Competitors are the stored peer set for LTGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Latigo Biotherapeutics Inc.
NASDAQ:LTGO
Intrinsic Alpha fair value
Locked
Current Price
$13.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.